In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antimicrobial resistance

This article was originally published in The Rose Sheet

Executive Summary

FDA, CDC and NIH will host public meeting Sept. 26 in San Diego, Calif. to solicit comments on development of Public Health Action Plan to Combat Antimicrobial Resistance. Discussion will center on second part of the action plan (global issues). Agencies held a meeting in June to discuss surveillance, prevention and control, research and product development. Evaluation of benefits and risks of antimicrobials in consumer products such as soap were included in action plan unveiled by HHS in 2001 (1"The Rose Sheet" Jan. 22, 2001, In Brief)...

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts